FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Results & Progress
10

Mounjaro — 12 Week Progress Report

Adriel Johnston·6 months ago
Twelve weeks in with Mounjaro and I wanted to give a thorough progress report. I have been tracking metrics closely since day one. The first noticeable change came around week 2-3: improved sleep quality. I went from waking up 2-3 times per night to sleeping through consistently. My sleep tracker confirmed what I was feeling — deep sleep increased by about 25 percent. By week 6, the recovery improvements were undeniable. Soreness after heavy training sessions dropped from 2-3 days to about 1 day. I was able to increase training frequency from 4 to 5 days per week without feeling overtrained. Body composition shifted gradually. I did not see dramatic scale changes, but my waist measurement dropped by about an inch while my weight stayed roughly the same. Clothes fit differently. A DEXA scan would have been nice but was not in my budget. Energy levels improved noticeably in the afternoon slump period. I used to rely on coffee around 2-3pm but have not needed it since about week 4. Overall I would rate Mounjaro as genuinely effective for my goals. Not a miracle but a meaningful improvement across multiple health markers.

Comments (8)

Dex FarrellDEMO·6 months ago

The sleep improvement you mention with Mounjaro has been the most universally reported benefit I see across different users. It seems like regardless of primary goals, almost everyone reports better sleep quality. I wonder if this is a direct effect or downstream from other physiological changes.

5
Lux ConwayDEMO·6 months ago

Thanks for the detailed protocol breakdown. I am starting Mounjaro next week and this is exactly the kind of practical information I was looking for. The reconstitution tips especially — I have seen conflicting advice elsewhere about water temperature and injection speed. Your approach sounds well-reasoned.

2
Cloud HarmonDEMO·6 months ago

Been following this thread with interest. My Mounjaro experience was similar in most ways, though I found the recovery benefits took a bit longer to kick in for me — closer to week 5-6 rather than 3-4. Individual variation is real and I think people need to be patient before concluding something is or is not working.

3
Rue HeathDEMO·6 months ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Mounjaro protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

4
Arrow JordanDEMO·6 months ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my Mounjaro journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

5
Kendall BaileyDEMO·6 months ago

The sleep improvement being the first noticeable change is a pattern I keep seeing across different compounds. It makes me wonder if sleep quality improvement is a leading indicator of systemic peptide response. Like a canary in a coal mine but positive.

0
Drew MarcosDEMO·6 months ago

Waist measurement dropping while weight stays stable is the definition of successful recomposition. This is why scale weight alone is a terrible metric for these protocols. DEXA would be ideal but even waist and neck measurements tell a better story.

0
Pax BakerDEMO·6 months ago

The afternoon energy improvement resonates with me. I was a 3pm coffee person for years. After 6 weeks on a similar protocol my energy is consistent throughout the day. I think this is related to improved deep sleep and better cortisol regulation.

0

Sign in to comment.